Prescient Design
Prescient Design has joined Genentech's Research and Early Development organization (gRED) in order to apply their cutting-edge technology and machine learning approach to our drug discovery efforts. We believe that Prescient Design's platform and expertise, combined with our growing internal computational capabilities, can ultimately help us bring better medicines to patients faster.
The Prescient Design Team
Founded by computer science and computational biology faculty members at New York University and the Flatiron Institute, the Prescient Design team has extensive expertise in the machine learning. They are focused on applying this cutting-edge technology to drug discovery.
Richard Bonneau
Co-Founder and Vice President of Machine Learning for Drug Discovery, Genentech Computational Sciences
See Profile
By bringing further advances in machine learning and artificial intelligence to Genentech, my goal is to help make the organization future-proof and develop potential medicines that treat diseases we haven’t been able to tackle.
Learn about groundbreaking research from our world-class scientists.
Advanced Computation and Data Science
Explore how we are applying computation & data science to deliver breakthrough medicines to patients.